BACKGROUND: Although screening of human immunodeficiency virus (HIV)-positive individuals for anal intraepithelial neoplasia (AIN; a precursor of anal cancer) has been practiced in San Francisco among HIV health care providers since the early 1990s, to the authors' knowledge no study to date has focused on evaluating recent AIN trends. METHODS: Cases of high-grade AIN 3 and invasive anal cancer from 2000 to 2009 were obtained from the San Francisco/Oakland Surveillance, Epidemiology, and End Results (SEER) population-based cancer registry. Age-standardized rates of AIN 3 and anal cancer were calculated overall and by demographic characteristics (sex, race, and age group). Log-linear regression calculated annual percent change in rates during 2000 to 2009, and rate ratios (RRs) and 95% confidence intervals (95% CIs), evaluated differences in rates during 2000 through 2004 and 2005 through 2009. RESULTS: During 2000 through 2009, the majority of AIN 3 cases occurred among men (1152 of 1320 men; 87.3%). Rates of AIN 3 during the corresponding period increased by 11.48% per year (P < .05) among men and were stable among women. Comparing rates among men during 2000 to 2004 with those during 2005 to 2009, the largest increases were noted among those aged 50 years to 64 years (RR, 2.47; 95% CI, 1.93-3.17) and among black individuals (RR, 3.49; 95% CI, 2.14-5.85). During the same period, anal cancer rates were stable among men and women. CONCLUSIONS: Rates of AIN 3 increased in San Francisco during 2000 through 2009, in conjunction with an anal cytology screening program for high-risk groups, whereas rates of invasive anal cancer were unchanged. Continued surveillance is necessary to evaluate the impact of screening and human papillomavirus vaccination on the prevention of human papillomavirus-related AIN and anal cancer.
BACKGROUND: Although screening of human immunodeficiency virus (HIV)-positive individuals for anal intraepithelial neoplasia (AIN; a precursor of anal cancer) has been practiced in San Francisco among HIV health care providers since the early 1990s, to the authors' knowledge no study to date has focused on evaluating recent AIN trends. METHODS: Cases of high-grade AIN 3 and invasive anal cancer from 2000 to 2009 were obtained from the San Francisco/Oakland Surveillance, Epidemiology, and End Results (SEER) population-based cancer registry. Age-standardized rates of AIN 3 and anal cancer were calculated overall and by demographic characteristics (sex, race, and age group). Log-linear regression calculated annual percent change in rates during 2000 to 2009, and rate ratios (RRs) and 95% confidence intervals (95% CIs), evaluated differences in rates during 2000 through 2004 and 2005 through 2009. RESULTS: During 2000 through 2009, the majority of AIN 3 cases occurred among men (1152 of 1320 men; 87.3%). Rates of AIN 3 during the corresponding period increased by 11.48% per year (P < .05) among men and were stable among women. Comparing rates among men during 2000 to 2004 with those during 2005 to 2009, the largest increases were noted among those aged 50 years to 64 years (RR, 2.47; 95% CI, 1.93-3.17) and among black individuals (RR, 3.49; 95% CI, 2.14-5.85). During the same period, anal cancer rates were stable among men and women. CONCLUSIONS: Rates of AIN 3 increased in San Francisco during 2000 through 2009, in conjunction with an anal cytology screening program for high-risk groups, whereas rates of invasive anal cancer were unchanged. Continued surveillance is necessary to evaluate the impact of screening and human papillomavirus vaccination on the prevention of human papillomavirus-related AIN and anal cancer.
Authors: Kenneth A Katz; Christina A Clarke; Kyle T Bernstein; Mitchell H Katz; Jeffrey D Klausner Journal: Ann Intern Med Date: 2009-02-17 Impact factor: 25.391
Authors: Irving E Salit; Jill Tinmouth; Sylvia Chong; Janet Raboud; Christina Diong; DeSheng Su; Marie Sano; Alice Lytwyn; William Chapman; James Mahony Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06-30 Impact factor: 4.254
Authors: Alexandra de Pokomandy; Danielle Rouleau; George Ghattas; Helen Trottier; Sylvie Vézina; Pierre Coté; John Macleod; Guy Allaire; Rachid Hadjeres; Eduardo L Franco; François Coutlée Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: Joel M Palefsky; Elizabeth A Holly; Jimmy T Efirdc; Maria Da Costa; Naomi Jay; J Michael Berry; Teresa M Darragh Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Ashish A Deshmukh; Elizabeth Y Chiao; Scott B Cantor; Elizabeth A Stier; Stephen E Goldstone; Alan G Nyitray; Timothy Wilkin; Xiaojie Wang; Jagpreet Chhatwal Journal: Cancer Date: 2017-09-26 Impact factor: 6.860
Authors: Yotam Arens; Michael Gaisa; Stephen E Goldstone; Yuxin Liu; Juan Wisnivesky; Carlie S Sigel; Talia H Swartz; Keith Sigel Journal: Dis Colon Rectum Date: 2019-08 Impact factor: 4.585
Authors: Rebecca G Nowak; Patti E Gravitt; Xin He; Sosthenes Ketende; Wuese Dauda; Helen Omuh; William A Blattner; Manhattan E Charurat Journal: Sex Transm Dis Date: 2016-04 Impact factor: 2.830
Authors: Meredith S Shiels; Aimée R Kreimer; Anna E Coghill; Teresa M Darragh; Susan S Devesa Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-29 Impact factor: 4.254
Authors: Nancy M Cladel; Lynn R Budgeon; Karla K Balogh; Timothy K Cooper; Jiafen Hu; Neil D Christensen Journal: PLoS One Date: 2015-03-24 Impact factor: 3.240